Clinical and Biomedical Proteomics Group, Cancer Research UK Centre, Leeds Institute of Molecular Medicine, St. James's University Hospital, Leeds, UK.
Proteomics Clin Appl. 2010 Mar;4(3):250-70. doi: 10.1002/prca.200900220. Epub 2010 Jan 7.
Biobanks with their collections of clinical samples and data are essential resources for the success of clinical proteomics in delivering and validating candidate biomarkers. Samples must be banked in a manner that allows maximum subsequent compatibility with analytical techniques and additionally many critical factors must be taken into account when establishing a biobank or selecting samples from a biobank. These include logistical, ethical, legal and security issues and, very importantly, steps to minimise any pre-analytical variability introduced through sample processing and handling (technical effects). The inherent variation present within the samples must also be taken into account. In this review, we examine the impact of these factors and issues to be faced when banking samples with a particular focus on sources of pre-analytical variation, which must be rigorously controlled and recorded. It is encouraging that several initiatives are now addressing such key issues and these are also discussed.
生物银行及其临床样本和数据的收集是临床蛋白质组学成功提供和验证候选生物标志物的关键资源。样本必须以允许与分析技术最大程度兼容的方式储存，此外，在建立生物银行或从生物银行中选择样本时，必须考虑许多关键因素。这些因素包括后勤、伦理、法律和安全问题，非常重要的是，要采取措施尽量减少样本处理和处理过程中引入的任何分析前变异性（技术影响）。还必须考虑到样本中存在的固有变异。在这篇综述中，我们检查了这些因素和在储存样本时需要面对的问题的影响，特别关注分析前变异性的来源，必须严格控制和记录这些来源。令人鼓舞的是，现在有几个举措正在解决这些关键问题，我们也将对此进行讨论。
